




Syndax Pharmaceuticals, Inc.
Investor Relations Department
35 Gatehouse Drive
Building D, Floor 3
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: SNDX

Last Trade:	11.13
Trade Time:	11:17 AM ET 08.21.17
Change:	0.23  (+2.110%)
Day Range	10.98 - 11.35
52-Week Range	6.31 - 18.03
Volume	8,028


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 08.10.17 [Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update](#)
- 08.03.17 [Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017](#)
- 07.11.17 [Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy](#)
- 05.24.17 [Syndax Prices Public Offering of Common Stock](#)
- 05.23.17 [Syndax Announces Proposed Public Offering of Common Stock](#)

Financial Information [\[View all \]](#)

- [Second Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 08.10.17 [Quarterly Report \(10-Q\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)
- 11.14.16 [Quarterly Report \(10-Q\)](#)